CorMedix Inc. (CRMD): Results of Operations and Financial Condition
CorMedix Inc. (CRMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 crmd_q22026earningspr.htm EX-99.1 Document Exhibit 99.1 CORMEDIX THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ‒ Q2 2026 Consolidated Revenue of $101.9 million ‒ ‒ Q2 2026 Net Income of $26.0 million ; Adjusted EBITDA of $58.7 m
How this was made
The 30-second read
Why it matters
The most tradable elements are the raised FY2026 adjusted EBITDA range, narrowed cash OpEx guidance, and the stated expected timing for REZZAYO sNDA submission and potential FDA action in H1 2027, alongside a new multi-year DefenCath supply agreement.
Market read
A same-day earnings and guidance update with explicit FY2026 targets and FDA submission timing typically drives immediate repricing and positioning ahead of the conference call.
What to watch
The filing notes higher operating expenses and legal-fee reimbursement credit; traders may focus on whether margin expansion persists after one-time or reimbursement-related items fade.
Background
This is CorMedix’s SEC 8-K (Item 2.02) with Q2 2026 results and an update on business priorities, including DefenCath commercial execution and REZZAYO regulatory progress.
Ticker impact
CorMedix reported Q2 2026 revenue of $101.9M, net income $26.0M, and raised FY2026 adjusted EBITDA guidance to $125-$140M.
Likely positive bias for the stock into the conference call and around FDA-review acceptance expectations, with upside tied to DefenCath utilization and sNDA acceptance.
The filing discloses multiple fresh, decision-relevant items: quarterly results, explicit FY guidance changes, and a stated expected timing for an FDA submission and potential H1 2027 agency action.
Market effects
Reinforces demand and contracting momentum in institutional dialysis supportive care products, potentially supporting sentiment for similar specialty pharma names.
Limited, primarily US small/mid-cap biotech sentiment via Nasdaq-listed CRMD.
Moderate, mainly through the Mundipharma collaboration and FDA timeline for REZZAYO, but no direct global macro linkage.
Counterpoint
Raised adjusted EBITDA guidance may reflect mix and acquisition contribution, so investors may discount durability if DefenCath reimbursement pressure worsens post-TDAPA.
Key entities
- issuerCorMedix Inc.
Nasdaq-listed biopharmaceutical company reporting Q2 2026 results and updated FY2026 guidance.
- productDefenCath
Taurolidine and heparin product whose Q2 net revenue and new supply agreement drive near-term commercial expectations.
- productREZZAYO
Product for which the company anticipates an FDA sNDA submission for expanded prophylaxis indication in Q3 2026.
- partnerMundipharma
Global development partner collaborating on the REZZAYO sNDA submission timeline.
